Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy. (7th April 2011)

• Record Type: Journal Article
• Authors: Ben Sellem, D.; Elbayed, K.; Neuville, A.; Moussallieh, F.-M.; Lang-Averous, G.; Piotto, M.; Bellocq, J.-P.; Namer, I. J.
• Other Names: Teng Nelson N. H. Academic Editor.
• Is Part Of: Journal of oncology. Volume 2011(2011)
• Publication Date: 2011-04-07
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2011/174019
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Objectives . The objectives of the present study are to determine if a metabolomic study by HRMAS-NMR can (i) discriminate between different histological types of epithelial ovarian carcinomas and healthy ovarian tissue, (ii) generate statistical models capable of classifying borderline tumors and (iii) establish a potential relationship with patient's survival or response to chemotherapy. Methods . 36 human epithelial ovarian tumor biopsies and 3 healthy ovarian tissues were studied using 1 H HRMAS NMR spectroscopy and multivariate statistical analysis. Results . The results presented in this study demonstrate that the three histological types of epithelial ovarian carcinomas present an effective metabolic pattern difference. Furthermore, a metabolic signature specific of serous (N-acetyl-aspartate) and mucinous (N-acetyl-lysine) carcinomas was found. The statistical models generated in this study are able to predict borderline tumors characterized by an intermediate metabolic pattern similar to the normal ovarian tissue. Finally and importantly, the statistical model of serous carcinomas provided good predictions of both patient's survival rates and the patient's response to chemotherapy. Conclusions . Despite the small number of samples used in this study, the results indicate that metabolomic analysis of intact tissues by HRMAS-NMR is a promising technique which might be applicable to the therapeutic management of patients.